文献速递乳房整形与再造美容整形

乳房植入物疾病症状在乳腺癌幸存者与隆胸受者间的比较

A comparison of Breast Implant Illness-related symptoms between breast cancer survivors and breast augmentation recipients.
PubMed 文献 · Plast Reconstr Surg · 2026-03-27

隆胸受者比有植入物的乳腺癌幸存者更常报告肌痛和食物不耐受,而不含植入物的乳腺癌幸存者并未报告更多BII症状。排除接受系统治疗的乳腺癌患者后,隆胸受者报告更多BII相关症状。

要点

  • 隆胸受者比有植入物的乳腺癌幸存者更常报告肌痛(OR 2.10)和食物不耐受(OR 1.77)。
  • 有植入物的乳腺癌幸存者未比无植入物的乳腺癌幸存者报告更多BII相关症状。
  • 排除系统治疗后,隆胸受者报告更多头痛、肌痛、脱发、肌无力、睡眠障碍和晨僵。

核心结论

  • 隆胸受者比有或无硅胶乳房植入物的乳腺癌幸存者报告更多BII相关症状。
  • 结果不支持BII是由跨人群共有的硅胶植入物相关发病机制介导的独立疾病实体。

研究设计与样本

  • 荷兰队列横断面调查,纳入578例隆胸受者和2884例乳腺癌幸存者(其中1039例接受硅胶乳房植入物再造)。

主要发现

  • 隆胸受者比有植入物的乳腺癌幸存者肌痛风险更高(OR 2.10,95%CI 1.25-3.54)。
  • 隆胸受者比有植入物的乳腺癌幸存者食物不耐受风险更高(OR 1.77,95%CI 1.01-3.09)。
  • 有植入物的乳腺癌幸存者未比无植入物的乳腺癌幸存者报告更多BII相关症状。
  • 排除接受(新)辅助系统治疗的乳腺癌患者后,隆胸受者报告更多头痛、肌痛、脱发、肌无力、睡眠障碍和晨僵(OR 1.69-3.35,均p<0.05)。

临床怎么用

  • 在乳腺癌幸存者硅胶植入物再造咨询中,可告知BII相关症状报告率可能低于隆胸受者。
  • 对隆胸受者主诉肌痛、食物不耐受等症状时应予以关注并与乳腺癌幸存者区分评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: 'Breast Implant Illness' (BII) refers to non-specific constitutional, rheumatic, mental and cognitive symptoms experienced by women with silicone breast implants (SBIs). This potential late effect of SBIs challenges the safety of SBI-use in oncologic breast reconstruction (BR). Previous studies on BII mainly focused on women with cosmetic SBIs. It remains unclear whether symptoms reported in this population differ from those reported by breast cancer (BC) survivors with SBI-based BR. METHODS: We conducted a cross-sectional survey in a Dutch cohort including 578 breast augmentation recipients and 2,884 BC survivors, of whom 1,039 had an SBI-based BR. Eighteen BII-related symptoms were assessed. Multivariable logistic regression was used to compare breast augmentation recipients with BC survivors with and without SBIs. RESULTS: Median follow-up time was 8.0 (IQR, 3.9) years. Overall, breast augmentation recipients had a higher risk of myalgia (Odds ratio (OR) 2.10, 95%CI [1.25-3.54]) and food intolerance (OR 1.77, 95%CI [1.01-3.09]) than BC survivors with SBIs, whereas the latter group did not report more BII-associated symptoms than BC survivors without SBIs. In a sensitivity analysis excluding BC patients treated with (neo)adjuvant systemic therapy, breast augmentation recipients reported more BII-related symptoms-headache, myalgia, hair loss, muscle weakness, sleep impairment, and morning stiffness (ORs 1.69-3.35; all p < 0.05) compared to BC survivors with SBIs. CONCLUSIONS: Breast augmentation recipients report more BII-related symptoms than BC survivors with or without SBIs. These findings do not support the hypothesis that BII is a distinct disease entity mediated by a generic SBI-related pathogenesis that exists across different populations.Trial registration: This study was preregistered at ClinicalTrials.gov on June 2 nd 2022 (NCT05400954).

来源:Plast Reconstr Surg,查看原文。版权归原作者所有。

引用

  1. Spoor J, van Leeuwen FE, de Jong D, et al. A comparison of Breast Implant Illness-related symptoms between breast cancer survivors and breast augmentation recipients. Plast Reconstr Surg. 2026. PMID: 41891787. doi:10.1097/PRS.0000000000013061

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。